Piper Sandler Maintains Overweight on Poseida Therapeutics, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Poseida Therapeutics (NASDAQ:PSTX) and increased the price target from $8 to $10.
December 11, 2023 | 4:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Poseida Therapeutics' stock may see a positive short term impact due to Piper Sandler's raised price target from $8 to $10 with an Overweight rating.
Analyst ratings and price target adjustments are significant indicators for investors. The increase from $8 to $10 by a reputable analyst at Piper Sandler suggests a strong conviction in Poseida Therapeutics' potential, likely leading to increased investor confidence and a positive short term price movement.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100